<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2966">
  <stage>Registered</stage>
  <submitdate>29/10/2010</submitdate>
  <approvaldate>29/10/2010</approvaldate>
  <nctid>NCT01231139</nctid>
  <trial_identification>
    <studytitle>The Paracetamol AfteR Traumatic Brain InjurY Study</studytitle>
    <scientifictitle>A Multi-centre Phase 2b Randomised Controlled Trial Investigating the Efficacy and Safety of Intravenous Paracetamol in Reducing Core Body Temperature After Traumatic Brain Injury</scientifictitle>
    <utrn />
    <trialacronym>PARITY</trialacronym>
    <secondaryid>PARITY</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Traumatic Brain Injury</healthcondition>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Other skin conditions</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Injuries and Accidents</conditioncode1>
      <conditioncode2>Other injuries and accidents</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Paracetamol
Treatment: drugs - 0.9% Sodium Chloride Schedule:

Experimental: Paracetamol - Paracetamol dissolved in 0.9% Sodium Chloride

Placebo Comparator: 0.9% Sodium Chloride - 0.9% Sodium Chloride


Treatment: drugs: Paracetamol
Intravenous paracetamol, 1 gram (100mls), administered over 30 minutes (every 4 hours for 3 days).

Treatment: drugs: 0.9% Sodium Chloride Schedule:
Identical placebo: 100mls saline given intravenous over 30 minutes (every 4 hours for 3 days)

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Core body temperature: bladder temperature probe</outcome>
      <timepoint>30 minutes after final dose of study drug has been administered</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Blood Pressure (systolic and mean arterial pressure) measured by intra-arterial pressure monitor</outcome>
      <timepoint>6 hourly during study treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Liver function test</outcome>
      <timepoint>daily from first dose of study treatment to the 7th day</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>serum Paracetamol levels (blood analysis) after a single dose of study drug and after final dose of study drug.</outcome>
      <timepoint>baseline, 30, 45, 90, 240 minutes after single dose. 240 minutes after final dose of study drug</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Temperature (bladder and tympanic) - Time-weighted mean, area under the 3-day temperature curve, daily maximum and minimum temperature</outcome>
      <timepoint>Hourly from first study drug treatment until 4 hours after final study drug treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The use of physical cooling interventions</outcome>
      <timepoint>hourly during the period of study intervention</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Intracranial pressure - Mean daily intracranial pressure for day 1, 2 and 3.</outcome>
      <timepoint>6 hourly during the period of study intervention</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of cerebral hypoperfusion - Systolic blood pressure &lt; 90 mmhg or Mean arterial pressure &lt; 50 mmhg for &gt; 15 minutes
Cerebral perfusion pressure &lt; 50 mmhg for &gt; 15 minutes</outcome>
      <timepoint>During study intervention period</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Written informed consent has been obtained from the patient's next of kin

          -  Age &gt; 18 and &lt; 65

          -  Non penetrating head injury requiring mechanical ventilation, and, with an abnormal CT
             head (defined by the presence of haemorrhage, contusion, swelling, compression of
             basal cisterns or herniation)

          -  Within 72 hours of injury

          -  Presence (or imminent placement) of arterial cannula

          -  Alanine transferase level &lt; 100</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Suspected paracetamol overdose or allergy to paracetamol

          -  Confirmed or suspected pregnancy

          -  Use of pharmacological or physical intervention that reduces body temperature in the
             6-hour period prior to randomisation.

          -  Clinician decision to institute any pharmacological or physical intervention that
             modifies body temperature

          -  Body temperature at time of recruitment less that 36°C or greater than 38.9°C

          -  History of chronic liver disease or chronic alcohol abuse

          -  Suspected malnutrition: BMI &lt; 18 kg/m2 or weight &lt; 60 kg

          -  BMI &gt; 35 kg/m2

          -  Renal failure with serum creatinine &gt; 200

          -  Haemodynamic instability defined as systolic blood pressure &lt; 90 mmhg or requirement
             for noradrenaline or adrenaline exceeding 20mcg/minute

          -  Use of hepatic enzyme inducers, except for phenytoin

          -  Minor head injury: either normal CT head or not expected to be in intensive care for
             72 hours

          -  GCS = 3 with fixed dilated pupils

          -  Moribund patient expected to die within 24 hours</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>41</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/06/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD</recruitmentstate>
    <hospital>St George Hospital - Sydney</hospital>
    <hospital>Royal Brisbane and Women's Hospital - Brisbane</hospital>
    <postcode> - Sydney</postcode>
    <postcode> - Brisbane</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Dr. M.K. Saxena</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>The George Institute</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>The University of New South Wales</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Royal Brisbane and Women's Hospital</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This primary aim is to investigate the effect of paracetamol in reducing body temperature in
      patients who have sustained traumatic brain injury. This study is also investigating the
      safety of paracetamol in this patient population.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01231139</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Manoj Saxena</name>
      <address>South East Sydney Illawarra Area Health Service</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>